From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)
Endpoint
95% CI
Response rate
10.1%
4.7-18.3%
Disease control rate
65.2%
54.3-75.0%
TTF
4.1 months
2.8-4.8 months
PFS
5.4 months
4.1-6.2 months
OS
14.5 months
11.8-17.0 months